Parkinson’s disease (PD) therapeutics innovation faces barriers in ensuring equitable access. High costs, regulatory delays, and distribution issues hinder patients globally, particularly in low- and middle-income countries (LMICs), limiting the market’s full impact.

Cost is a primary issue: orphan drugs cost $100k+/year (e.g., Kynmobi’s $150/month U.S. price). Even generics (levodopa) face shortages, spiking prices. A 2023 International Parkinson’s Alliance survey found 45% of African PD patients rely solely on generics. To explore these challenges, the Parkinson’s Medication Accessibility Challenges section in Market Research Future’s report examines regional disparities and solutions.

Regulatory and logistical hurdles delay access. LMICs take years to approve new drugs; specialized storage (biologics) and administration (gene therapy) are unavailable in rural areas. Only 5% of sub-Saharan African PD patients access advanced therapies (2023 IPA data). These gaps limit market growth, as many can’t afford new treatments.

Efforts to improve access include pharma’s patient programs (Novartis’ free India initiative) and WHO’s prequalification. As the market grows ($15B+ revenue by 2030, MRF data), ensuring innovation benefits all patients is vital. Closing accessibility gaps will maximize PD therapeutics’ global impact.